Anders Jacobson
Director/Board Member bei KLARIA PHARMA HOLDING AB
Vermögen: 6 378 $ am 31.03.2024
Profil
Anders Jacobson is currently the Deputy Chairman at MD Biomedical AB.
He is also an Independent Director at Klaria Pharma Holding AB and the Chief Innovation Officer at Senzime AB.
Previously, he served as a Director at Acarix AB from 2020 to 2021.
Mr. Jacobson holds a graduate degree from the University of Uppsala.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SENZIME AB
0,01% | 30.12.2022 | 11 000 ( 0,01% ) | 6 378 $ | 31.03.2024 |
Aktive Positionen von Anders Jacobson
| Unternehmen | Position | Beginn |
|---|---|---|
| SENZIME AB | Corporate Officer/Principal | 01.02.2022 |
| KLARIA PHARMA HOLDING AB | Director/Board Member | 01.01.2022 |
MD Biomedical AB
 MD Biomedical AB Medical/Nursing ServicesHealth Services Part of Senzime AB, MD Biomedical AB provides micro dialysis products and services. The private company is based in Umeå, Sweden. The Swedish company was founded in 2011 by Pernilla Abrahamsson. MD Biomedical was acquired by Senzime AB on April 21, 2015 for $0.24 million. | Director/Board Member | - |
Ehemalige bekannte Positionen von Anders Jacobson
| Unternehmen | Position | Ende |
|---|---|---|
| ACARIX AB | Director/Board Member | 11.05.2021 |
Ausbildung von Anders Jacobson
| University of Uppsala | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SENZIME AB | Health Technology |
| ACARIX AB | Health Technology |
| KLARIA PHARMA HOLDING AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
MD Biomedical AB
MD Biomedical AB Medical/Nursing ServicesHealth Services Part of Senzime AB, MD Biomedical AB provides micro dialysis products and services. The private company is based in Umeå, Sweden. The Swedish company was founded in 2011 by Pernilla Abrahamsson. MD Biomedical was acquired by Senzime AB on April 21, 2015 for $0.24 million. | Health Services |
